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bias when comparing costs and utilization between insulin lispro
and regular human insulin users. METHODS: A retrospective
analysis of medical and pharmacy claims was conducted among
users of insulin lispro or regular insulin during the identiﬁcation
period, March 1, 2000 to February 28, 2001. Propensity scores
(PS) were estimated using age, gender, comorbidities, use of oral
antidiabetic medications, prescription copayment, and baseline
period diabetes-related costs and utilization. Our binning analy-
ses classiﬁed all patients into ﬁve PS strata (quintiles). Overall
cost and utilization differences during the 12-month follow-up
period were then calculated using weights inversely proportional
to variances of within bin differences. In our matched analyses,
all subjects who could not be “paired” (1 :1 lispro to regular
insulin) with PS estimates agreeing within ±0.0001 were
excluded. RESULTS: Of 6436 subjects, 1972 (30.6%) received
insulin lispro and 4464 (69.4%) received regular insulin. At
baseline, lispro subjects were younger, had fewer comorbidities,
and were less likely to use oral antidiabetic medications than
regular insulin users. Within PS quintiles, there was no signiﬁ-
cant imbalance on baseline characteristics. When matching, only
969 well-matched subject pairs could be retained. Baseline char-
acteristics of these well-matched subjects were similar to those
of subjects in quintiles 3 and 4, indicating that matching had
tended to exclude subjects with extreme combinations of char-
acteristics (quintiles 1 and 5). CONCLUSIONS: Relative to
matching, the binning approach to adjustment for treatment
selection bias appears to provide an answer that is more easily
generalized to our full diabetic population. The binning
approach uses all available outcome data to estimate overall
treatment differences. Our analyses suggest that restrictions on
insulin lispro availability to save pharmacy costs may not be 
economically justiﬁable from a more comprehensive payer’s 
perspective.
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OBJECTIVES: The Cardiff Diabetes Cost Utility Model is a dis-
crete-event stochastic simulation model used to model macrovas-
cular and microvascular complications in diabetes. The model
was based on the Eastman DCCT model, and forecasts costs and
outcomes over a 20-year period using the UKPDS risk engines
for estimating cardiovascular events. This study used the Cardiff
model to estimate quality-adjusted life years (QALYs) and cost
of secondary care for patients with type-2 diabetes. METHODS:
Health utility was incorporated via the EQ5D utility instrument
using estimates derived from the Health Outcomes Data Repos-
itory (HODaR). This diabetes model accurately incorporates
health utility estimates for patients with individual and multiple
complication states. The model was run using baseline risk pro-
ﬁles used by Eastman and was compared with a 10% change in
individual and combined modiﬁable risk factors. We evaluated
the impact of these changes on the costs of secondary care events,
excluding drug costs. Costs were discounted at 6% and beneﬁts
at 1.5%. RESULTS: At baseline, the total discounted cost of 
hospital events was £5841 (£3305 for cardiovascular events 
and £2536 for microvascular events). Following a 10% change
in one of three modiﬁable risk factors, hospital event costs and
QALYs gained were driven by the total cholesterol to high-
density lipoprotein cholesterol ratio (TC:HDL-C) (-£392; 0.23
QALYs) and glycated hemoglobin (HbA1c) level (-£1236; 0.44
QALYs). TC:HDL-C had the greatest impact on cardiovascular
costs (-£423), and HbA1c had the greatest impact on microvas-
cular costs (-£890). These results were dependent on the age of
the population modeled: as age increased, HbA1c had less impact
on events and costs and TC:HDL-C had more impact. CON-
CLUSIONS: This study further demonstrates the importance of
TC:HDL-C and HbA1c on cost of macro- and microvascular
complications, respectively. This economic model is the ﬁrst to
reliably evaluate beneﬁt in terms of health utility.
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OBJECTIVES: To analyze the pharmacy and medical care 
costs of using different insulin-delivery methods, including pen-
injectors, disposable syringes, and traditional injection; and
examine the prevalence of hypoglycemic and hyperglycemic
events among patients on different delivery methods.
METHODS: Utilizing pharmacy and medical claims from a
managed care plan of over two million members, this study
selected continuously enrolled patients who received insulin or
insulin delivery products between July 1, 2000 and June 30,
2001, but did not have claims for these products in the six
months prior to the index date. The patients were divided into
three analysis groups based on initial insulin delivery method:
pen-injector, disposable syringe, or traditional injection. Phar-
macy and medical utilization, costs, and prevalence of hypo-
glycemic or hyperglycemic events in the 18 months following
index date were compared among the 3 groups. RESULTS:
Among the 3278 patients who received insulin products in the
12 months from July 1, 2000 to June 30, 2001, nearly 88% took
the traditional injection approach, only 12% adopted the deliv-
ery devices, including 146 patients (4.45%) who used pen injec-
tors and 250 patients (7.63%) who used disposable syringes.
Log-transformed linear regressions showed that pen-injector and
disposable users cost 58.5% and 50.3%, respectively, more than
patients using traditional injections in pharmacy expenditures,
but not in medical services expenditures, controlling for patient
demographics, comorbidities, community characteristics, and
type of health plan. Controlling for the same covariates, a logis-
tic regression indicated that the likelihood of having hypo-
glycemic or hyperglycemic events was similar between
traditional injection and the devices (p > 0.05). CONCLUSION:
This study did not ﬁnd signiﬁcant difference in medical costs and
insulin-related health events between patients who took insulin
via traditional injection and those adopted pen injectors or dis-
posable syringes, although traditional injections were less costly.
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OBJECTIVES: A telecommunications company, a founding
member of the Leapfrog Group, undertook this study to evalu-
ate its costs for retirees with Type-2 diabetes and the quality of
care received. METHODS: Health care costs were evaluated for
those with 6 months continuous enrollment prior to, and 12
months after, an initial Type 2 diabetes medical service noted in
a claims database. Vascular complications (cardio-, cerebro-,
micro- and peripheral) were grouped into a cohort hierarchy for
analysis. Cost differences were estimated among groups adjust-
ing for age, gender and severity of concurrent conditions.
RESULTS: The mean age of the population (N = 9959) was 74.4
years; 50% were female. Adjusted annual costs for those without
hospitalizations ranged from $4877 with no complications to
$12,271 with four complications. For those with hospitaliza-
tions, adjusted annual costs ranged from $18,839 with one com-
plication to $41,011 with 4 complications. Each group was
signiﬁcantly different (p < 0.001) from the no complication
group. Average annual costs per beneﬁciary with/without 
hospitalizations were cardiovascular (excluding hyperten-
sion), $11,128/$22,952; hypertension, $7656/$17,927; stroke,
$15,349/$25,333. No antidiabetic drug was present in 4360
(44%) beneﬁciaries in the 12-month period after the initial dia-
betes medical service. Of the 5599 prescribed an antidiabetic
drug, 2072 (37%) received a sulfonylurea only; 913 (16%)
received a sulfonylurea and metformin; 698 (12%) received met-
formin only; 566 (10%) received insulin only; and, 573 (10%)
received a thiazolidinedione alone or in combination. CON-
CLUSIONS: Type-2 diabetes produces signiﬁcant health care
expenditures by an employer, its retirees and Medicare. Despite
a generous prescription beneﬁt, drug treatment patterns suggest
misuse of agents with known adverse effects and underuse of
agents with evidence-based therapeutic beneﬁts. These results
will support a targeted, evidenced-based, employer-sponsored
intervention to improve quality-of-care and patient safety by
focusing on drug treatment appropriate for the individual’s 
circumstances.
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OBJECTIVE: To quantify the effect of diabetes-related hypo-
glycemia on direct health care costs and utilization. METHODS:
The sample consisted of 9162 privately insured employees that
had at least 12 months of continuous enrollment between
January 1, 1999 and December 31, 2001, and two or more pre-
scriptions for diabetes-related medications within the same ther-
apeutic class (insulin, sulfonylurea, or other oral diabetes-related
medication) from Medstat’s Health Productivity and Manage-
ment database. Patients were grouped into two cohorts: hypo-
glycemia or non-hypoglycemia depending on whether they
incurred a diagnosis of hypoglycemia (ICD-9-CM 250.8, 251.1,
251.2). The sample was further sub-set to those with claims for
insulin (N = 2664)—64% of the original sample. Data were gath-
ered starting from the ﬁrst evidence of a diabetes-related med-
ication. RESULTS: The incidence of hypoglycemia did not vary
signiﬁcantly by age, insurance type, or region of the country.
However, the hypoglycemia group had evidence of signiﬁcantly
increased comorbidity including renal disease (14% vs. 6%, 
p < 0.01), ophthalmic ﬁndings (42% vs. 30%, p < 0.01), and
neuropathy (30% vs. 15%, p < 0.01), as well as a higher 
mean Charlson Comorbidity Index (1.20 vs. 0.75, p < 0.01).
Hypoglycemia patients incurred on average twice as many hos-
pitalizations (1.0 vs. 0.5, p < 0.01) and emergency room visits
(0.8 vs. 0.4, p < 0.01) annually compared to insulin-users
without hypoglycemia. Forty percent (40%) of the excess hos-
pitalizations and 53% of the excess emergency room visits were
associated with a hypoglycemia diagnosis. Hypoglycemia
patients on insulin incurred twice the amount of overall health
care expenditures ($28,049 vs. $14,019, p < 0.01) and three
times the amount of diabetes-related health care expenditures
($14,590 vs. $5236, p < 0.01) compared to non-hypoglycemia
insulin users. CONCLUSION: Hypoglycemia contributed sig-
niﬁcantly to medical care utilization and health care expenditures
among patients using insulin. Analysis of the indirect costs
among this population as well as investigation into hypoglycemia
among diabetes patients on oral agents warrants further investi-
gation.
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OBJECTIVES: Diabetes disproportionately affects the poor and
medically underserved minorities, populations typically served
by State Medicaid programs. This study sought to assess the pat-
terns of diabetes-related health care costs incurred by the Texas
Medicaid program for Hispanics, African-Americans, and Cau-
casians with type-2 diabetes. METHODS: Treatment-naïve adult
patients in 2000 were identiﬁed. Total costs were assessed in the
12-months following the initiation of therapy, deﬁned as the ﬁrst
ﬁlling of a prescription following 6 months of no such prescrip-
tion. Patient demographic and disease severity measures as well
as county level variables were evaluated. To assess factors asso-
ciated with treatment cost, bivariate and multivariate linear
regression analyses were performed, where log transformed cost
was used as a dependent variable. RESULTS: Resource utiliza-
tion patterns and treatment costs of patients with type-2 diabetes
differ among the race and ethnic groups studied. In the ﬁrst year
of diabetes management, total treatment costs for Hispanics
($7189) and ($6715) were substantially lower than for white
patients ($8549). Although the difference in health care costs
between Caucasians and African-Americans was mostly
accounted for by demographic, clinical, and county level vari-
ability, the cost difference between Hispanics and Caucasians still
persisted with regard to these factors. CONCLUSIONS: The
immediate cost to care for patients with type-2 diabetes is 
substantial in this Medicaid population, regardless of race or 
ethnicity. Moreover, the differences in costs between the groups
are substantial, suggesting that race- or ethnicity-related factors
associated with persistence need to be addressed in optimizing
early therapy.
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OBJECTIVES: Painful neuropathy is a common complication of
diabetic patients. The purpose of this study is to compare the
cost-effectiveness of duloxetine to routine treatment in the 
